Therma Bright Acquires 100% Control of its COVID-19 Rapid Saliva Antigen Test and Announces Proposed Name Change for the Test
As a result, Therma Bright will retain 100% of all future revenue and profits from the sale of the saliva-based rapid antigen test.
- As a result, Therma Bright will retain 100% of all future revenue and profits from the sale of the saliva-based rapid antigen test.
- Therma Bright will no longer pursue that arrangement with Torion Biosciences Inc., with 100% of the future economic benefit now flowing directly to Therma Bright Inc.
- In addition, Therma Bright will create a new trademark name for its saliva-based rapid antigen test, temporarily called SCV2, until a new name is protected.
- Therma Bright will now procure sufficient test kits to be used in the prospective studies to occur in the month of February.